(Q24235594)

5

0 references

Michael Soyka

6

object named as

Michael Soyka

0 references

author name string

Susanne Rösner

1

0 references

Andrea Hackl-Herrwerth

2

0 references

Philippe Lehert

Cochrane Database of Systematic Reviews

4

0 references

publication date

8 September 2010

0 references

published in

0 references

cites work

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Acamprosate and its efficacy in treating alcohol dependent adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term treatment outcomes for alcohol dependence improved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Using topiramate or naltrexone for the treatment of alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Acamprosate and psychosocial intervention. An integrative treatment approach for prevention of alcohol dependent patients in Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

A comparison of two intensities of psychosocial intervention for alcohol dependent patients treated with acamprosate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

The effect of acamprosate on alcohol and food craving in patients with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Adjuvant drug treatment of alcoholism with acamprosate: between sectoral budgets and disease management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Effects of acamprosate on sleep during alcohol withdrawal: A double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Cochrane Database of Systematic Reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

A comparison of statistical methods for meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Acamprosate blocks the increase in dopamine extracellular levels in nucleus accumbens evoked by chemical stimulation of the ventral hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Does acamprosate improve reduction of drinking as well as aiding abstinence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Compelling or irrelevant? Using number needed to treat can help decide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Effects of acamprosate on ethanol-seeking and self-administration in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Alcoholics Anonymous and other 12-step programmes for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Meta-analysis of continuous outcome data from individual patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Quality of Reporting of Randomized Trials as a Measure of Methodologic Quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Effectiveness of brief alcohol interventions in primary care populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Lack of effects of Ca-acetyl homotaurinate on chronic and acute toxicities of ethanol in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Acamprosate: recent findings and future research directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

The anti-relapse compound acamprosate inhibits the development of a conditioned place preference to ethanol and cocaine but not morphine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Brief interventions for heavy alcohol users admitted to general hospital wards

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Rates and predictors of relapse after natural and treated remission from alcohol use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Intention-to-treat analysis: implications for quantitative and qualitative research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Confirmation bias: A ubiquitous phenomenon in many guises

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Statistical problems in the reporting of clinical trials. A survey of three medical journals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Undue reliance on I(2) in assessing heterogeneity may mislead

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Subverting randomization in controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Alcohol abusers' perceptions of the accuracy of their self-reports of drinking: implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

A multilevel model framework for meta-analysis of clinical trials with binary outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Outcome selection bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Analysing Data and Undertaking Meta-Analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

7 January 2021

Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

7 January 2021

Comparison of acamprosate and placebo in long-term treatment of alcohol dependence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

7 January 2021

Alcohol dependence syndrome: measurement and validation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

7 January 2021

Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

7 January 2021

Acamprosate appears to decrease alcohol intake in weaned alcoholics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

7 January 2021

Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

7 January 2021

Pharmacology of acamprosate: an overview.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

7 January 2021

Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

7 January 2021

The Michigan Alcoholism Screening Test: The Quest for a New Diagnostic Instrument

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

7 January 2021

Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

7 January 2021

Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

7 January 2021

The efficacy of compliance therapy in pharmacotherapy for alcohol dependence: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

7 January 2021

Direct and indirect costs attributable to alcohol consumption in Germany

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004332.PUB2

7 January 2021

10.1002/14651858.CD004332.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

20824837

1 reference

Consolidated OpenCitations Corpus – April 2017